{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:29:53Z","timestamp":1771327793732,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,23]],"date-time":"2002-01-23T00:00:00Z","timestamp":1011744000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p>Objective.\u2014To investigate the tolerability and efficacy of rizatriptan 5 mg in adolescent migraineurs.<\/jats:p>\n                  <jats:p>Methods.\u2014Randomized, double\u2010blind, placebo\u2010controlled study. Patients aged 12 to 17 years received rizatriptan 5 mg (n=149) or placebo (n=147) for a moderate or severe headache and for up to two recurrences. Headache severity, presence or absence of associated symptoms, and functional disability were assessed over a 4\u2010hour postdose period, and any adverse events were recorded. The primary efficacy measure was pain\u2010free status at 2 hours postdose.<\/jats:p>\n                  <jats:p>\n                    Results.\u2014Rizatriptan 5 mg was well tolerated. The most commonly reported adverse events (all with incidence of 5% or less) among patients receiving rizatriptan were dry mouth, dizziness, asthenia\/fatigue, nausea, and somnolence. The percentage of patients pain\u2010free at 2 hours was 32% for rizatriptan 5 mg versus 28% for placebo (\n                    <jats:italic>P<\/jats:italic>\n                    =.474). The percentage of patients with pain relief (reduction of predose pain intensity to mild or none) at 2 hours was 66% for rizatriptan versus 56% for placebo (\n                    <jats:italic>P<\/jats:italic>\n                    =.079). Placebo response rates were higher than those typically observed in previous studies of rizatriptan in adults. Compared with placebo, rizatriptan significantly improved functional disability at 1.5 and 2 hours, and nausea at 1 and 1.5 hours. Post hoc analysis showed a significant benefit of rizatriptan versus placebo in the percentage of patients who had pain relief when their migraine attacks were treated on weekends (65% versus 36%,\n                    <jats:italic>P<\/jats:italic>\n                    =.046) compared with weekdays (66% versus 61%,\n                    <jats:italic>P<\/jats:italic>\n                    =.365), and the weekend placebo response rate was similar to that seen in adults.\n                  <\/jats:p>\n                  <jats:p>Conclusions.\u2014Rizatriptan 5 mg was well tolerated and effective on some measures when used in adolescents for the treatment of a migraine attack.<\/jats:p>","DOI":"10.1046\/j.1526-4610.2002.02013.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T06:49:38Z","timestamp":1027666178000},"page":"49-55","source":"Crossref","is-referenced-by-count":121,"title":["Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study"],"prefix":"10.1111","volume":"42","author":[{"given":"Paul","family":"Winner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Hester","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith K.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"On Behalf Of The Rizatriptan Adolescent Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6957.765"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420150061038"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.5.989"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1505404.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.103"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1507"},{"key":"e_1_2_6_8_2","first-page":"424","article-title":"Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of acute migraine in adolescents (12\u201017 years) [abstract].","volume":"40","author":"Pitman V","year":"2000","journal-title":"Headache"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.1100"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1999.9.35"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804281.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3810748.x"},{"key":"e_1_2_6_13_2","first-page":"411","article-title":"Pharmacokinetics of rizatriptan in adolescent migraineurs [abstract].","volume":"38","author":"Winner P","year":"1998","journal-title":"Headache"},{"issue":"7","key":"e_1_2_6_14_2","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.","volume":"8","author":"Headache Classification Committee of the International Headache Society","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.773"},{"key":"e_1_2_6_16_2","first-page":"319","article-title":"Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine [abstract].","volume":"37","author":"Lines C","year":"1997","journal-title":"Headache"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-4610.2002.02013.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-4610.2002.02013.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:05:54Z","timestamp":1762088754000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-4610.2002.02013.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1046\/j.1526-4610.2002.02013.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-4610.2002.02013.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}